Phase 3 Clinical Trial in Adult Growth Hormone Deficiency with TransCon hGH

Brief description of study

The primary objective of this trial is to assess the efficacy of once-weekly lonapegsomatropin compared to placebo in adults with growth hormone deficiency (GHD). The daily somatropin product arm is included to provide a concurrent assessment of standard of care in this patient population. In addition to assessing efficacy, a treatment duration of approx. 9 months is considered adequate to assess safety and is supported by the well-characterized safety of daily somatropin products for adult growth hormone deficiency (AGHD) and extensive clinical experience for lonapegsomatropin for pediatric GHD at higher doses than used in AGHD.

Clinical Study Identifier: s20-00241 Identifier: NCT04615273

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.